I would like to see some column inches trumpeting the success of the firm and its potential pipeline of innovative products. The other investors we need to get this stock motoring up are not aware- let posting on here 24th April! and this is a success story with the SP waiting to fly
Sorry have to disagree. Thought it was nine sales in 6 months which were a lot higher than last year though if I remember correctly last year was poor as customers waited for the new release. I think the fact that revenue has started to come in for affirmers is a good sign and as biotech's start to understand the benefits of the arrays, sales should climb. With good profit margins this should lead to profits also climbing. Don't forget Affirmers are cheaper and quicker than the current alternative. This just needs communicating to the market which I admit will take time but the news will spread out. Another few tests for the sensipod and this should also help drive sales. Long term hold with a slow pick up in share price and sales as each new test is launched. Hopefully.
I brought in a couple of years ago after researching the company. I was landed by the MD's comments about the company being at an inflection point in its history. So in two years we have gone from being loss making to err being loss making. I love AIM and its bullish MD's who talk such a great game. I sure they are very well paid for their hot air. 9 sales in a year, worries me, if the tech is that good it will sale itself, one sale every 6 weeks means something is wrong. Another one for the bottom draw.
has completed development and validation of a new test for pancreatitis in dogs.
Pancreatitis is a very common inflammatory disorder of the pancreas in dogs of which there are 83 million in the US and 8.5 million in the UK. The acute form of the disease occurs in around 1.5% of dogs whilst the prevalence of the chronic form is reported to be as high as 30% suggesting a large market for a pancreatitis diagnostic test. However, the market is even larger than the prevalence of the disease alone would suggest because most dogs with pancreatitis present with common gastrointestinal signs of upset, such as vomiting, anorexia, painful abdomen, hunched posture, diarrhoea, fever, dehydration and lack of energy; with vomiting being the most common symptom. Consequently, a much larger number of animals would be screened for pancreatitis than may eventually be diagnosed with the disorder.
Avacta's new pancreatitis test utilises the same approach as its unique canine lymphoma blood test in which an algorithm is used to combine the results of two common blood tests with other symptoms and other information about the dog such as age and breed. Currently there is only one other proprietary test for pancreatitis in the market. Avacta's internal validation of its new pancreatitis test performance shows that is has better sensitivity, specificity and predictive capability than the established test when tested on confirmed pancreatitis cases clinically diagnosed by vets at a large referral centre in the UK using other techniques such as ultrasound.
Avacta will commercialise the test by providing "pay per click" access to the diagnostic algorithm which will allow veterinary laboratories world wide to get an accurate and immediate diagnosis for pancreatitis by submitting the results of two blood tests commonly run in house along with other patient information on-line. In due course the blood tests themselves will also be offered on the Sensipod in-clinic analyser allowing vets to access the same on-line pancreatitis diagnostic.
We are Walbrook PR who handle the financial PR for Avacta Group PLC. If you are interested in taking a virtual tour of the premises, please see the link attached. If you would like to tour the facility, we will be able to organise this so please contact us at firstname.lastname@example.org
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.